Pralsetinib in the treatment of pleomorphic xanthoastrocytoma with RET‑activated: A case report
Experimental and Therapeutic Medicine · 19.11.2026 · 33 (1) · 1-6
DOI: 10.3892/etm.2026.13364 ↗Kurz gefasst
Fallbericht in der Zeitschrift Experimental and Therapeutic Medicine, online erschienen am 19.11.2026. Verfasst von Huayang Zhao und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Rearranged during transfection (RET)‑activated gliomas are exceptionally rare and associated with a poor prognosis, and there are no established effective therapies. Clinical data on RET inhibitors are predominantly derived from solid tumors such as non‑small cell lung cancer and medullary thyroid carcinoma, with data for central nervous system tumors being scarce. The present report describes a case of pleomorphic xanthoastrocytoma with RET activation that progressed following the Stupp regimen but subsequently exhibited a favorable response to pralsetinib, teniposide and bevacizumab. The tumor area decreased from 4.84 cm2 before treatment to 1.92 cm 2 (calculated based on the longest and maximum perpendicular diameters).
Zitieren
APA
Zhao, H., Sun, P., Pan, X., Wang, H., Li, Y., Zheng, Y., Tao, R., & Zhou, S. (2026). Pralsetinib in the treatment of pleomorphic xanthoastrocytoma with RET‑activated: A case report. Experimental and Therapeutic Medicine, 33(1), 1-6. https://doi.org/10.3892/etm.2026.13364
Vancouver
Zhao H, Sun P, Pan X, Wang H, Li Y, Zheng Y, et al. Pralsetinib in the treatment of pleomorphic xanthoastrocytoma with RET‑activated: A case report. Experimental and Therapeutic Medicine. 2026;33(1):1-6. doi:10.3892/etm.2026.13364
BibTeX
@article{Zhao2026,
author = {Zhao, Huayang and Sun, Peng and Pan, Xueqiang and Wang, Hui and Li, Yan and Zheng, Yueliang and Tao, Rongjie and Zhou, Shizhen},
title = {Pralsetinib in the treatment of pleomorphic xanthoastrocytoma with RET‑activated: A case report},
journal = {Experimental and Therapeutic Medicine},
year = {2026},
volume = {33},
number = {1},
pages = {1--6},
doi = {10.3892/etm.2026.13364}
}
EUVIMED